Apimeds Pharmaceuticals US, Inc.
APUS NYSE
SEC CIK 1894525
Follow Apimeds Pharmaceuticals US
Weekly email: filings, results
Revenue, last quarter
$2.9M
Net income
$33.6M
+1988.9% vs same quarter last year
EPS, diluted
$7.68
+640.8% vs same quarter last year
Operating cash flow
−$218.6K
+87.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$6M |
| FY24 | −$1.4M |
| FY23 | −$777.7K |
| FY22 | - |